Benjamin Hohl - Dec 22, 2023 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
Chief Financial Officer
Signature
/s/ Benjamin Hohl
Stock symbol
ELVN
Transactions as of
Dec 22, 2023
Transactions value $
-$14,223
Form type
4
Date filed
12/27/2023, 05:26 PM
Previous filing
Apr 6, 2023
Next filing
Jan 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Options Exercise $2.55K +1.03K $2.48* 1.03K Dec 22, 2023 Direct F1
transaction ELVN Common Stock Sale -$15.5K -1.03K -100% $15.07 0 Dec 22, 2023 Direct F1, F2
transaction ELVN Common Stock Options Exercise $248 +100 $2.48* 100 Dec 26, 2023 Direct F1
transaction ELVN Common Stock Sale -$1.5K -100 -100% $15.00 0 Dec 26, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Employee Stock Option (right to buy) Options Exercise $0 -1.03K -0.39% $0.00 261K Dec 22, 2023 Common Stock 1.03K $2.48 Direct F1, F3
transaction ELVN Employee Stock Option (right to buy) Options Exercise $0 -100 -0.04% $0.00 261K Dec 26, 2023 Common Stock 100 $2.48 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $15.00 to $15.24. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 The option, originally for 262,120 shares, vested as to one-fourth of the shares vests on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter.